Genova was founded in 2007 with the vision to deliver affordable biopharmaceuticals with the highest quality standards to the vast majority of patients worldwide through its proprietary, leading-edge and cost-effective recombinant protein bioprocesses. It aims to become a leading low-cost manufacturer of high-quality pharmaceutical-grade protein products for the global markets, and to provide contract technical services for bio-process development and protein manufacturing to companies worldwide.

Its product portfolio, the current global markets for which is US$30 billion, includes 5 insulin and insulin analogs. As well as somatropin, a human growth hormone, all of which will benefit the 500 million diabetic patients in China and across the world.